A practical review of the EU ingredient-name glossary, a UK eye-cosmetic safety action, volume-led beauty growth in emerging markets, and two formulation signals for color cosmetics and lightweight skincare.
1. The updated EU glossary of common ingredient names now applies
Commission Implementing Decision (EU) 2025/1175 applies from 30 July 2026 and repeals Decision (EU) 2022/677. The glossary supports the ingredient names used for cosmetic labelling under Regulation (EC) No 1223/2009; it is not a positive list of ingredients authorised for cosmetic use.
For an export project, the practical task is version control. Ingredient names in supplier documents, formula bills of materials, labels and the Product Information File should be checked against the same current naming source. Colourants should also be reviewed using the applicable CI nomenclature.
Recommended output: an SKU-level difference register with three states - verified, supplier confirmation required, and legacy name not to be carried forward.
2. A UK eye-cosmetic enforcement case highlights batch evidence
On 29 July 2026, the UK Office for Product Safety and Standards published a serious-risk report for Hashmi Kajal Eyeliner. The report states that the sampled product contained mercury, cadmium, arsenic and lead and was withdrawn from sale.
This is a product-specific enforcement case, not evidence about every kajal or pigment. Its development lesson is still useful: near-eye colour cosmetics need traceable raw-material batches, impurity specifications, suitable test methods and records that connect incoming material evidence to the finished-product release decision.
Recommended output: a near-eye pigment and mineral-powder evidence matrix covering batch number, COA scope, test method, relevant impurity results and unresolved supplier questions.
3. Public company results point to volume-led beauty growth in emerging markets
Unilever reported first-half 2026 underlying sales growth of 5.9% for Beauty & Wellbeing and 4.8% for Personal Care, with most of that growth attributed to volume. The company also reported growth in India, Indonesia and China and described premium innovation and digital execution as contributors.
One company's results cannot be treated as a market forecast. They can, however, guide prototype questions: low-residue hair repair, fragrance-led body care, and sensory stability under hot and humid conditions are practical areas to test for high-frequency products.
Recommended output: country-specific prototype briefs that separate climate, channel, sensory target, fragrance direction, price architecture and regulatory assumptions.
4. Foundation development needs a shade-performance matrix
Public trend trackers continue to show interest in deeper shade ranges and warm, natural-light makeup looks. These signals should not be converted into a universal claim about which shade will sell in every market.
A stronger development response is to connect shade depth and undertone with dispersion, coverage, oxidation, sebum exposure, transfer and high-temperature wear. Pigment treatment, optical powders, film formers and oil control should be evaluated as one system.
Recommended output: a shade-by-performance matrix rather than a single hero shade or a social-media label presented as market proof.
5. Lightweight, discreet care concepts need claim discipline
Search and short-video signals around transparent spot patches, lash serums and comfort after intensive active routines suggest demand for products that are discreet, fast-drying and easy to layer with makeup.
These signals are not clinical efficacy evidence. Development can focus on transparent film formation, low tack, moisturising comfort, pilling control and makeup compatibility while avoiding treatment, healing or drug-like wording.
Recommended output: a prototype comparison covering film visibility, dry-down, tack, pilling, foundation compatibility and temperature stability, accompanied by a market-specific claim review.
Evidence and use boundary
Prepared from public first-party and regulatory sources. This brief is for industry orientation only; market-specific legal, safety and claim decisions require review of the current official text and product-specific evidence.